Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior... see more

Recent & Breaking News (TSX:MDNA)

Medicenna Receives Regulatory Clearance to Expand the Phase 1/2 ABILITY Study of MDNA11 to Canada

GlobeNewswire December 17, 2021

Medicenna Receives Award for Excellence in Clinical Trials in Connection with an Upcoming Presentation at the 26th Annual Meeting of the Society for Neuro-Oncology

GlobeNewswire November 18, 2021

Medicenna (TSX:MDNA) provides second quarter 2022 financial and operational highlights

Julia Kennedy  November 12, 2021

Medicenna Reports Second Quarter Fiscal 2022 Financial Results and Operational Highlights

GlobeNewswire November 12, 2021

Medicenna Therapeutics to Present at Stifel's Virtual Healthcare Conference

GlobeNewswire November 9, 2021

Medicenna Therapeutics to Announce Second Quarter 2022 Financial Results and Operational Highlights on Friday, November 12, 2021

GlobeNewswire November 4, 2021

Medicenna’s (TSX:MDNA) receives FDA clearance to expand MDNA11 study

Brieanna McCutcheon  October 27, 2021

Medicenna Announces FDA Clearance of IND to Expand the Phase 1/2 ABILITY Study of MDNA11 to the United States

GlobeNewswire October 27, 2021

Medicenna Presents MDNA11 Data from IND-Enabling Studies at the AACR-NCI-EORTC Conference

GlobeNewswire October 7, 2021

Medicenna Appoints Dr. John H. Sampson to its Board of Directors

GlobeNewswire September 23, 2021

Medicenna Presenting at Next-Gen Cytokine Therapeutics Summit

GlobeNewswire September 22, 2021

Medicenna Announces Issuance of U.S. Patent Providing Added Intellectual Property Protection for its MDNA11 Program

GlobeNewswire September 20, 2021

Medicenna Doses First Patient in MDNA11 Phase 1/2 ABILITY Study

GlobeNewswire September 14, 2021

Medicenna Therapeutics to Present at Upcoming September Investor Conferences

GlobeNewswire September 9, 2021

Medicenna (TSX:MDNA) off to a strong start for fiscal year 2022

Julia Kennedy  August 13, 2021

Medicenna Reports First Quarter Fiscal 2022 Financial Results and Operational Highlights

GlobeNewswire August 13, 2021

Medicenna to Announce First Quarter Fiscal 2022 Financial Results and Operational Highlights on Friday, August 13, 2021

GlobeNewswire August 4, 2021

Medicenna Announces That Initiation of MDNA11 Phase 1/2 Study is on Track; Update to be Provided at the PropThink Digital Conference

GlobeNewswire July 27, 2021

Medicenna's IL-2 Superkine Platform Featured in Peer-Reviewed Publication Demonstrating its Superiority and Ability to Reprogram the Tumor Microenvironment in Pancreatic Cancer

GlobeNewswire July 14, 2021

Medicenna (TSX:MDNA) submits clinical trial application for a Phase 1/2 study of MDNA11

Brieanna McCutcheon  June 23, 2021